A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
XL820-001
NCT00129571
August 2005
Name | Location |
---|---|
Cancer Therapy and Research Center | San Antonio, Texas 78229 |
The Cancer Institute of New Jersey | New Brunswick, New Jersey 08901 |